Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie k hodnocení dlouhodobé bezpečnosti inlacumabu podávaného účastníkům se srpkovitou anémií

29. října 2026 aktualizováno: Pfizer

Otevřená rozšiřující studie k vyhodnocení dlouhodobé bezpečnosti inlacumabu podávaného účastníkům se srpkovitou anémií, kteří se zúčastnili klinického hodnocení inlacumabu

This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.

Přehled studie

Detailní popis

The study will include approximately 520 adult and adolescent participants (≥ 12 years of age) with SCD.

All participants will receive inclacumab 30 mg/kg administered intravenously every 12 weeks.

Typ studie

Intervenční

Zápis (Aktuální)

241

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Rio de Janeiro, Brazílie, 20211-030
        • Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti - HEMORIO
      • São Paulo, Brazílie, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, Brazílie, 01232-010
        • Hospital Samaritano Higienópolis/Esho Empresa De Servicos Hospitalares S.A
      • São Paulo, Brazílie, 08270-120
        • CEPEC-Centro de Pesquisa Clinica
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazílie, 41253-190
        • Instituto D'Or de Pesquisa e Ensino - Hospital São Rafael
    • Pernambuco
      • Recife, Pernambuco, Brazílie, 50070-460
        • Multihemo Servicos Medicos S/A
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazílie, 90035-903
        • Hospital de Clínicas de Porto Alegre
    • São Paulo
      • Ribeirão Preto, São Paulo, Brazílie, 14051-140
        • Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP
      • São José do Rio Preto, São Paulo, Brazílie, 15090-000
        • Fundação Faculdade Regional de Medicina de São José do Rio Preto
      • Eldoret, Keňa, 30100
        • International Cancer Institute
      • Nairobi, Keňa, 00100
        • Gertrude's Children's Hospital
      • Nairobi, Keňa, 00100
        • Kenya Medical Research Institute - Centre for Respiratory Disease Research
      • Nairobi, Keňa, 00200
        • Strathmore University CREATES
    • Siaya County
      • Kisumu, Siaya County, Keňa, 40600
        • KEMRI/CRDR Siaya Clinical Research Annex
    • Atlántico
      • Barranquilla, Atlántico, Kolumbie, 080020
        • Clinica de la Costa Ltda.
    • Cesar Department
      • Valledupar, Cesar Department, Kolumbie, 200001
        • Sociedad de Oncología y hematología del Cesar
    • Beirut
      • Hamra, Beirut, Libanon
        • American University of Beirut Medical Center
    • North Lebanon
      • Tripoli, North Lebanon, Libanon
        • Nini Hospital
      • Enugu, Nigérie, 460000
        • University of Nigeria Teaching Hospital
      • Kaduna, Nigérie, 800212
        • Barau Dikko Teaching Hospital/Kaduna State University
      • Kano, Nigérie, 700223
        • Aminu Kano Teaching Hospital
      • Lagos, Nigérie, 100254
        • Department of Pediatrics, College of Medicine, Lagos University Teaching Hospital
    • Cross River State
      • Calabar, Cross River State, Nigérie, 540242
        • University of Calabar Teaching Hospital
    • Federal Capital Territory
      • Abuja, Federal Capital Territory, Nigérie, 900211
        • National Hospital Abuja
      • Gwagwalada, Federal Capital Territory, Nigérie, 902101
        • University of Abuja Teaching Hospital
    • Kaduna State
      • Zaria, Kaduna State, Nigérie, 810105
        • Ahmadu Bello University Teaching Hospital
      • Muscat, Omán, 123
        • Sultan Qaboos University Hospital
    • Southern
      • Jizan, Southern, Saudská arábie, 82943
        • Prince Mohammed bin Nasser Hospital
    • Alabama
      • Mobile, Alabama, Spojené státy, 36604
        • University of South Alabama Children's and Women's Hospital
      • Mobile, Alabama, Spojené státy, 36604
        • Strada Patient Care Center, Pediatric Hematology
      • Mobile, Alabama, Spojené státy, 36606
        • South Alabama Medical Science Foundation
    • Arkansas
      • Little Rock, Arkansas, Spojené státy, 72202
        • Arkansas Children's Hospital
    • California
      • Orange, California, Spojené státy, 92868
        • UC Irvine Medical Center
    • Connecticut
      • Farmington, Connecticut, Spojené státy, 06030
        • UConn-Neag Comprehensive Cancer Center
    • Illinois
      • Chicago, Illinois, Spojené státy, 60612
        • University of Illinois Hospital and Health Sciences System (UI Health)
      • Chicago, Illinois, Spojené státy, 60612
        • University of Illinois at Chicago (UIC) Clinical Research Center
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Spojené státy, 02215
        • Dana-Farber Cancer Institute IDS Pharmacy
      • Boston, Massachusetts, Spojené státy, 02115
        • Brigham And Woman's Hospital
    • Michigan
      • Ann Arbor, Michigan, Spojené státy, 48109
        • University of Michigan Hospitals - Michigan Medicine
    • New York
      • The Bronx, New York, Spojené státy, 10461
        • Jacobi Medical Center
    • North Carolina
      • Durham, North Carolina, Spojené státy, 27705
        • Duke University Medical Center
      • Durham, North Carolina, Spojené státy, 27710
        • DUMC Investigational Drug Services Pharmacy
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • McGovern Medical School at UTHealth
      • Houston, Texas, Spojené státy, 77030
        • UT Physicians Comprehensive Sickle Cell Center Houston
      • Houston, Texas, Spojené státy, 77030
        • UT Health Science Center at Houston - Clinical Research Unit at Memorial Hermann Hospital
      • Dar es Salaam, Tanzanie, 11101
        • National Institute for Medical Research (NIMR)
      • Adana, Turecko (Türkiye), 01130
        • Acibadem Adana Hastanesi Cocuk Hematoloji Onkoloji
      • Adana, Turecko (Türkiye), 01250
        • Baskent University Adana Appl. and Research Central, Yuregir Baskent Hospital Hematology
      • Ankara, Turecko (Türkiye), 06430
        • Hacettepe University Ihsan Dogramaci Children Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

12 let a starší (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

Participants who meet all the following criteria will be eligible for study enrollment:

  1. Male or female participant with SCD who participated and received study drug in a GBT-Sponsored inclacumab clinical study.

  2. Participant has completed the originating inclacumab study within 30 calendar days of the Day 1 Visit. Participants who discontinued study drug in the originating study due to a non-study drug-related AE, but who remained on study, may be eligible for treatment in this study provided the AE does not pose a risk for treatment with inclacumab.

  3. Female participants of childbearing potential are required to have a negative urine pregnancy test prior to dosing on Day 1.

    Note: Female participants who become of childbearing potential during the study must be willing to have a negative urine pregnancy test to remain in the study.

  4. If sexually active, female participants of childbearing potential must consistently use highly effective methods of contraception consistently throughout the study and for at least 165 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 165 days after the last dose of study drug.

  5. Participant has provided written informed consent/assent. For underage participants, both the consent of the participant's legal representative or legal guardian and the participant's assent (where applicable) must be obtained based on local requirement.

Exclusion Criteria:

Participants meeting any of the following exclusion criteria will not be eligible for study enrollment:

  1. Female participant who is breastfeeding or pregnant.
  2. Participant had an infusions-related reaction (IRR) in the originating inclacumab clinical study.
  3. Participant withdrew consent from the originating inclacumab clinical study.
  4. Participant was lost to follow-up from the originating inclacumab clinical study.
  5. Participant has any medical, psychological, safety, or behavioral conditions that, in the opinion of the Investigator, may confound safety interpretation, interfere with compliance, or preclude informed consent.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Inclacumab 30 mg/kg

Inclacumab 30 mg/kg administered intravenously (IV)

Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

An adverse event (AE) was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A TEAE was defined as an AE with an onset after the initiation of dosing for the first dose of study drug in current study GBT2104-133 (NCT05348915). TEAEs included both serious and all other AEs.

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Annualized Rate of Vaso-occlusive Crises (VOCs)
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of VOCs That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC that required admission to a healthcare facility and treatment with parenteral pain medication was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in admission to a healthcare facility; 3) required parenteral narcotic agents or parenteral NSAIDs. Admission to a healthcare facility included: 1) a hospital admission or 2) an admission to an emergency room, observation unit, or infusion center for >= 12 hours or 3) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period. Annualized rate of VOC = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Number of Inpatient Hospitalization Days for a VOC
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Annualized rate of hospitalization days = (total number of hospitalization days)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of SCD-related Urgent Care Visits
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Urgent care visits included visits to the clinic, emergency room, and hospital. Analysis of this outcome measure included both VOC and non-VOC SCD-related events. Annualized rate of visits = (total number of visits)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Percentage of Total Days Missed From School or Work Due to SCD Pain Symptoms for the First 48 Weeks
Časové okno: From first dose of study treatment (Day 1) up to Week 48

The percentage of total days missed from school or work due to SCD pain symptoms out of the total expected days of school or work attendance for the first 48 weeks of the study is presented in this outcome measure.

From first dose of study treatment (Day 1) up to Week 48
Annualized Rate of Complicated VOCs
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

A VOC was defined as an acute episode of pain that: 1) had no medically determined cause other than a vaso-occlusive event; 2) resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or resulted in a remote contact with a healthcare provider; 3) required parenteral narcotic agents, parenteral NSAIDs, or an increase in treatment with oral narcotics. Complicated VOCs included acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism. Annualized VOC rate = (total number of VOC events)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)
Annualized Rate of Red Blood Cell (RBC) Transfusions
Časové okno: From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Annualized RBC transfusion rate = (total number of RBC transfusions)/(total person-years).

From first dose of study treatment (Day 1) up to the end of study (an average of 90.2 weeks, maximum of 182.7 weeks)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Ředitel studie: Pfizer CT.gov Call Center, Pfizer

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

29. března 2022

Primární dokončení (Aktuální)

7. listopadu 2025

Dokončení studie (Aktuální)

7. listopadu 2025

Termíny zápisu do studia

První předloženo

29. března 2022

První předloženo, které splnilo kritéria kontroly kvality

21. dubna 2022

První zveřejněno (Aktuální)

27. dubna 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

29. října 2026

Naposledy ověřeno

1. října 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit